The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
27 08 2020
Historique:
received: 28 01 2020
revised: 01 06 2020
accepted: 07 06 2020
pubmed: 1 7 2020
medline: 28 4 2021
entrez: 1 7 2020
Statut: ppublish

Résumé

Influenza is associated with significant morbidity and mortality worldwide. Whilst vaccination is key for the prevention of influenza infection, there are many factors which may contribute to reduced vaccine effectiveness, including antigenic evolution via both antigenic drift and egg-adaptations. Due to the currently dissociated and indirect evidence supporting both the occurrence of these two phenomena in the egg-based manufacturing process and their effects on vaccine effectiveness, this topic remains a subject of debate. To review the evidence and level of agreement in expert opinion supporting a mechanistic basis for reduced vaccine effectiveness due to egg-based manufacturing, using an expert consensus-based methodology and literature reviews. Ten European influenza specialists were recruited to the expert panel. The overall research question was deconstructed into four component principles, which were examined in series using a novel, online, two-stage assessment of proportional group awareness and consensus. The first stage independently generated a list of supporting references for each component principle via literature searches and expert assessments. In the second stage, a summary of each reference was circulated amongst the experts, who rated their agreement that each reference supported the component principle on a 5-point Likert scale. Finally, the panel were asked if they agreed that, as a whole, the evidence supported a mechanistic basis for reduced vaccine effectiveness due to egg-based manufacturing. All component principles were reported to have a majority of strong or very strong supporting evidence (70-90%). On reviewing the evidence for all component principles, experts unanimously agreed that there is a mechanistic basis for reduced vaccine effectiveness resulting from candidate influenza virus variation due to egg-based manufacturing, particularly in the influenza A/H3N2 strain. Experts pointed to surveillance, candidate vaccine virus selection and manufacturing stages involving eggs as the most likely to impact vaccine effectiveness.

Identifiants

pubmed: 32600916
pii: S0264-410X(20)30794-5
doi: 10.1016/j.vaccine.2020.06.021
pii:
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6047-6056

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sankarasubramanian Rajaram (S)

Seqirus, Maidenhead, UK. Electronic address: Raja.Rajaram@seqirus.com.

Radek Wojcik (R)

Medialis Ltd, Banbury, UK.

Catherine Moore (C)

Wales Specialist Virology Centre, Public Health Wales, Cardiff, UK.

Raúl Ortiz de Lejarazu (R)

Valladolid National Influenza Centre, Valladolid, Spain. Electronic address: lejarazu@gmail.com.

Simon de Lusignan (S)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Royal College of General Practitioners Research and Surveillance Centre, London, UK.

Emanuele Montomoli (E)

University of Siena, Siena, Italy.

Alessandro Rossi (A)

Società Italiana di Medicina Generale (SIMG), Florence, Italy.

Alberto Pérez-Rubio (A)

Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Antoni Trilla (A)

Hospital Clínic - University of Barcelona, Barcelona, Spain.

Vincenzo Baldo (V)

University of Padova, Padova, Italy.

Ravi Jandhyala (R)

Medialis Ltd, Banbury, UK.

George Kassianos (G)

Royal College of General Practitioners, British Global and Travel Health Association, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH